SCP
COGT icon

Sender Company & Partners’s Cogent Biosciences COGT Stock Holding History

Sender Company & Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,861
Closed -$419K – 62
2021
Q4 		$419K Buy
+48,861
New +$425K 0.21% 78

Other funds holding COGT

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Sender Company & Partners's COGT Position: Q1 2022 in Review

Sender Company & Partners sold out of Cogent Biosciences (COGT) in Q1 2022, closing a stake of 48,861 shares — an estimated $419K sold.

Sender Company & Partners first reported a position in COGT in Q4 2021 and held it in 1 quarter. The position peaked at $419K in Q4 2021. 87 funds tracked by Wall St. Rank hold COGT as of Q1 2022.

  • Sender Company & Partners reported no remaining Cogent Biosciences position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 48,861 Cogent Biosciences shares in Q1 2022, an estimated $419K.
  • Sender Company & Partners first reported a position in Cogent Biosciences in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Cogent Biosciences position peaked at $419K in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.